The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or zim+chemo followed by adjuvant dom+zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC).
 
Ahad Ali Sadiq
Honoraria - MSD
Speakers' Bureau - BMS Norway
 
Sivan Shamai
Consulting or Advisory Role - Janssen; Medison
Travel, Accommodations, Expenses - Roche
 
Sheng-Hao Lin
No Relationships to Disclose
 
Ji-Youn Han
Stock and Other Ownership Interests - Yuhan
Honoraria - AstraZeneca; Janssen; Merck; Novartis; Pfizer; Takeda; Yuhan
Consulting or Advisory Role - ABION; Bristol-Myers Squibb; J Ints Bio; Janssen; Lantern Pharma; Merck; Novartis; Pfizer; Takeda
Research Funding - Ono Pharmaceutical; Pfizer; Roche; Takeda
 
Shobhit Baijal
Consulting or Advisory Role - Abbvie; Agilent; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Foundation One Inc; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; SERVIER; Takeda
Speakers' Bureau - Abbvie; Agilent; Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Foundation One Inc; Gilead Sciences; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Takeda
Research Funding - Abbvie; AstraZeneca; Daiichi Sankyo; Foundation One Inc; Gilead Sciences; GlaxoSmithKline; Janssen; Merck Sharp & Dohme; Pfizer; Roche
Travel, Accommodations, Expenses - Roche; Takeda
 
Ozan Yazici
No Relationships to Disclose
 
Carlos H. Barrios
Stock and Other Ownership Interests - MedSIR; Tummi
Honoraria - Adium Pharma; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Zodiac Pharma
Consulting or Advisory Role - AstraZeneca; Libbs; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aveo (Inst); Bayer (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Covance (Inst); Daiichi Sankyo (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); ICON Clinical Research (Inst); INC Research (Inst); IQvia (Inst); Janssen (Inst); LabCorp (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Nuvisan (Inst); OBI Pharma (Inst); Parexel (Inst); Parexel (Inst); Pfizer (Inst); PharmaMar (Inst); PPD Global (Inst); PSI (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Servier (Inst); Syneos Health (Inst); Takeda (Inst); TRIO US (Inst); Worldwide Clinical Trials (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Jie Zhang
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Kun Chen
Employment - Gilead Sciences
Stock and Other Ownership Interests - Abbvie; Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Young Kim
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Joseph Park
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Christoph Matthias Ahlers
Employment - Arcus Biosciences; Replimune
Stock and Other Ownership Interests - GlaxoSmithKline
Travel, Accommodations, Expenses - Arcus Biosciences; GlaxoSmithKline; Replimune
 
Nir Peled
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Guardant Health; Imagene; Lilly; Merck; MSD; Novartis; Novocure; Pfizer; Renium; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Guardant Health; Imagene AI; Lilly; Merck; MSD; Novartis; Novocure; Pfizer; Renium; Roche; Takeda
Speakers' Bureau - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Guardant Health; Imagene AI; Lilly; Merck; MSD; Novartis; Novocure; Pfizer; Renium; Roche; Takeda
Research Funding - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Gaudant360; Imagene AI; Lilly; Merck; MSD; Novartis; Novocure; Pfizer; Renium; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Guardant Health; Imagene; Merck; MSD; Novartis; Pfizer; Renium; Roche; Takeda